| 300705 | 九典制 | 0.44 | 3.37 | 660.10 | 3.35 | | --- | --- | --- | --- | --- | --- | | | 药 | | | | | | 600572 | 康恩贝 | 0.68 | 1.45 | 627.79 | 3.76 | | 002349 | 精华制 | 0.81 | 2.27 | 571.95 | 4.13 | | | 药 | | | | | | 002004 | 华邦健 | 0.25 | 0.80 | 571.40 | 9.29 | | | 康 | | | | | | 688553 | 汇宇制 | 1.93 | 1.88 | 555.55 | 5.80 | | | 药 | | | | | | 300086 | 康芝药 | -0.39 | 3.88 | 517.25 | 5.87 | | | 业 | | | | | | 002907 | 华森制 | 3.77 | 5.14 | 493.67 | 2.10 | | | 药 | | | | | | 000908 | *ST景峰 | 1.19 | 2.66 | 475.12 | 3.98 | ...

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of 1.2 yuan per 10 shares for all shareholders, based on a total share capital of 1,249,800,000 shares after excluding repurchased shares [2][6]. Group 1: Profit Distribution Plan - The total share capital of the company is 1,279,800,000 shares, with 30,000,000 shares in the repurchase account excluded, resulting in a base of 1,249,800,000 shares for the cash dividend distribution [2][6]. - The total cash dividend amount is calculated to be 149,976,000 yuan, which translates to a per-share cash dividend of approximately 0.1171870 yuan after considering the total share capital [10]. - The profit distribution plan was approved at the shareholders' meeting held on May 14, 2025, and the implementation of the plan will occur within two months of this approval [5][4]. Group 2: Dividend Payment Details - The record date for the dividend distribution is set for May 28, 2025, and the ex-dividend date is May 29, 2025 [7]. - The cash dividends will be directly credited to the accounts of shareholders through their respective securities companies on the ex-dividend date [9]. - The company will not withhold individual income tax for certain shareholders, with tax obligations determined based on the holding period of the shares [6]. Group 3: Shareholder Rights and Adjustments - Shares repurchased by the company will not participate in the profit distribution, losing rights to dividends and other benefits [6]. - The distribution method ensures that the total share capital remains unchanged post-distribution, although the per-share dividend will decrease due to the fixed total cash dividend amount [10]. - The company has provided contact information for inquiries regarding the dividend distribution process [8].

证券代码：002550 证券简称：千红制药 公告编号：2025-014 常州千红生化制药股份有限公司 关于 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）2024 年度 权益分派方案为：以公司现有总股本 1,279,800,000 股剔除回购专用账户中股数 30,000,000 股，按 1,249,800,000 股为基数，向全体股东每 10 股派发现金红利 1.2 元（含税），本次利润分配方案不送红股，不以公积金转增股本，采用分配比例 固定的原则进行。按总股本折算每 10 股现金红利=实际现金分红总额/总股本*10 股=149,976,000 元÷1,279,800,000 股*10 股=1.171870 元（保留六位小数，最后一 位直接截取，不四舍五入）。 公司 2024 年度权益分派方案已获 2025 年 5 月 14 日召开的 2024 年度股东 大会审议通过，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配及资本公积金转增股本方案等情况 ...

上海邦信阳律师事务所 关于常州千红生化制药股份有限公司 2024 年年度股东大会 之 法律意见书 二〇二五年五月 致：常州千红生化制药股份有限公司 上海邦信阳律师事务所（以下简称"本所"）接受常州千红生化制药股份有限 公司（以下简称"公司"）的委托，指派律师出席并见证公司于2025年5月14日召 开的常州千红生化制药股份有限公司2024年年度股东大会（以下简称"本次股东 大会"），并就本次股东大会的相关事项出具法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1、本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称 "《证券法律业务管理办法》"）、等法律、法规和规范性文件以及《常州千红生化 制药股份有限公司章程》（以下简称"《公司章程》"）的有关规定，就本次股东大 会的召集召开程序、出席会议人员资格、召集人资格、会议登记方式、会议表决 程序及表决结果的合法合规性、有效性进行核查，并出具本法律意见书。 2、本所律师不对本次股东大会审议 ...

证券代码：002550 证券简称：千红制药 公告编号：2025-013 常州千红生化制药股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议的情形。 一、会议召开情况 （一）召开时间： 1、现场会议召开时间：2025 年 5 月 14 日（周三）下午 14:00 2、网络投票时间：2025 年 5 月 14 日 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 14 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 14 日 上午 9:15 至下午 15:00 期间的任意时间。 （二）召开地点：公司云河路厂区二楼会议室（江苏省常州市新北区云河路 518 号） （三）召开方式：现场与网络会议方式 （四）召集人：公司董事会 （五）主持人：公司董事长王耀方先生 本次股东大会采用现场表决与网络投票相结 ...

Group 1: Company Performance and Financials - The company's revenue has been declining primarily due to a decrease in the sales prices of major products, although sales volume increased in 2024 compared to the previous year [4] - The company aims for sustainable annual growth in net profit excluding non-recurring items, focusing on the biopharmaceutical sector [4] - The company reported that its existing products have not been significantly affected by national procurement policies, although some regional impacts were noted [6] Group 2: Research and Development - The company has increased its R&D investment, but the results are not expected to yield direct economic benefits within the next three years; however, they will drive long-term growth [4] - The company is focusing on innovative drug development, with ongoing projects primarily in oncology and cardiovascular fields, aiming to complete key clinical trials by 2026 [7] - The company has submitted a registration application for its generic drug LSA02, which is intended for diabetes treatment [5] Group 3: Market Strategy and Challenges - The company is implementing a dual-circulation model for domestic and international markets, which has helped mitigate impacts from the US-China trade war [3] - The company is facing challenges from regional procurement policies affecting product pricing [4] - The company plans to enhance its market share through brand influence and product quality, especially in the context of contract renewals [8] Group 4: Investor Relations and Future Outlook - The company is committed to strengthening investor relations and will continue to engage positively with investors [9] - The company is preparing for a convertible bond issuance with a target of raising up to 1 billion yuan, with ongoing preparations for the application [7] - The company anticipates a positive overall business development in 2025, encouraging investors to monitor regular reports for updates [8]

证券代码：002550 证券简称：千红制药 公告编号：2025-012 常州千红生化制药股份有限公司 可登录公司官方微信平台（公众号名称："千红制药"）中"互动 交流"栏目，点击"投资者互动"即可参与本次说明会。千红制药微 信公众号见下图： 出席本次说明会的人员有：董事长王耀方先生；董事、总经理王 轲先生；独立董事宁敖先生；董事会秘书、财务负责人姚毅先生。 关于举行 2024 年度报告网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"公司"）将于 2025 年 4 月 30 日（星期三）下午 15:00-16:00 在全景网提供的网上平台举 行 2024 年度报告网上说明会，本次说明会将采用网络远程方式举行： （一）PC 端投资者 可登陆投资者互动平台：http://rs.p5w.net/c/002550.shtml 参与本次 说明会； （二）手机端投资者 常州千红生化制药股份有限公司 董 事 会 为充分尊重投资者、提升交流的针对性，现就公司 2024 年度网 上业绩说明会提前向投资者公开征集问题，广泛听 ...

证券代码：002550 证券简称：千红制药 4、2025 年原料药业务展望如何，其中海外需求和 价格趋势如何？毛利率趋势如何？ 目前，原料药业务订单情况良好，海外需求整体呈 现平稳趋势，但相较历史高峰期水平仍处于偏弱态势。 基于当前国内外市场联动性强、供需稳定的外部生态环 境，若无美国关税政策干扰，预计全年原料药价格将保 持平稳趋势。然而，倘若美国对中国肝素加征关税导致 出口受阻，可能引发不确定性的连锁反应，最终肝素价 格走势需持续观察关税政策实际影响，目前尙无法精准 预判。当前公司业务暂未受显著影响，但需警惕后续市 场结构性波动。 肝素原料药业务的毛利率，预计 2025 年整体毛利 率较 2024 年将呈小幅下降趋势，主要原因为终端销售 价格呈下行趋势，但成本端保持稳定。尽管如此，得益 于规范市场的价格支撑，叠加上游成本端的平稳因素， 单位毛利额得以保障，2025 年公司肝素原料药业务毛 利率仍将处于历史较高水平。 常州千红生化制药股份有限公司 投资者关系活动记录表 编号： | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | | □新 ...

Summary of Qianhong Pharmaceutical Conference Call Company Overview - **Company**: Qianhong Pharmaceutical - **Year**: 2024 - **Profit**: 269 million CNY, up 87.48% YoY, with ROE at 14.73% [1][2] - **Q1 2025 Performance**: Revenue down 2% YoY, but net profit up 54.6% due to improved gross margin and trust compensation [1][2] Key Financial Highlights - **2024 Sales Revenue**: 1.53 billion CNY, down 15.8% YoY [2] - **Net Profit**: 356 million CNY, up 95.7% YoY; non-recurring net profit at 269 million CNY, up 87.48% YoY [2] - **Earnings Per Share**: 0.28 CNY [2] - **Cash Flow from Operations**: 514 million CNY, slightly lower than last year but still strong [2] Clinical Project Updates - **Project 107**: Completed Phase 2A with data better than historical combination therapy data; conditional Phase 2 trial to start in September [1][4] - **Project 106**: Phase 2 unblinding completed; plans to communicate with CDE in May and start Phase 3 in September [1][4] - **QHRD211**: Entered Phase 2 clinical trials, expected to submit for market approval in 2028 [1][4] - **QHRD114**: Received clinical trial approval for solid tumors [1][4] - **Project 109**: Expected to submit IND application in mid-2024 [1][4] Raw Material Business Outlook - **2025 Expectations**: Optimistic outlook for raw material business with historical order levels; expected sales growth [1][5] - **Heparin Demand**: Stable global demand with prices expected to remain steady, but potential fluctuations due to US tariffs [1][6] - **Sales Projections**: Heparin raw material sales expected to grow, with gross margin above 30% [3][10] Product Sales and Market Strategy - **Sulfate Ertapenem**: Expected annual sales between 250 million to 300 million CNY if restructuring is completed [1][7] - **Qianmu Project**: Expected to start production in June 2025, projected to generate approximately 150 million CNY in revenue [1][9] - **OTC Sales Growth**: Compound digestive enzyme product sales expected to increase by 50% post-collaboration with Bayer [3][11] Market Challenges and Opportunities - **Market Access Loss**: Lost market access in some provinces but offset by growth in other markets; potential recovery of lost market share post-collection [1][13] - **Impact of Tariffs**: US tariffs may affect pricing dynamics in other markets, particularly Europe [1][19] Research and Development - **R&D Investment**: 150 million CNY in R&D for 2024, with a focus on innovative drug development [1][15][16] - **Future Strategy**: Shift towards innovative drug development to diversify product offerings [1][17] Conclusion - **Overall Performance**: Qianhong Pharmaceutical shows strong financial performance with significant profit growth and optimistic projections for raw material and clinical projects. The company is navigating market challenges while focusing on innovation and strategic partnerships to enhance its market position.

医药 2025 年 04 月 21 日 千红制药(002550.SZ) 24年利润端实现快速增长，创新管线有望贡献弹性 推荐（维持） | 叶寅 | 投资咨询资格编号 | | --- | --- | | | S1060514100001 | | | BOT335 | | | YEYIN757@pingan.com.cn | | 研究助理 | | | 臧文清 | 一般证券从业资格编号 | | | S1060123050058 | | | ZANGWENQING222@pingan.com.cn | 事项： 2025 年 4 月 19 号，千红制药发布 2024 年年报和 2025 年一季报，24 年共实 现收入 15.26 亿元（-15.88%），归母净利润 3.56 亿元（+95.77%），扣非后归 母净利润 2.69 亿（+87.48%），利润端实现快速增长。利润分配预案：每 10 股 派发现金红利 1.2 元（含税）。25Q1 公司实现收入 4.51 亿元（-2.22%），归母 净利润 1.61 亿元（+54.62%），主要系收回部分建元信托前期逾期款项，扣非 后归母净利润 1.07 亿（+4.84%）。 ...